Aura Biosciences announced today that it will participate in the Boston Miles for Melanoma 5K Run/Walk, in support of the Melanoma Research Foundation’s (MRF) research, advocacy and education efforts.
Elisabet de los Pinos, Aura's founder and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference in New York, N.Y. The presentation will take place on Tuesday, April 12, 2016, at 2:40 p.m. EDT.
We are Developing a New Class of Therapies to Target and Destroy Cancer Cells Selectively
Current treatments for cancers like ocular melanoma are highly invasive and often imprecise and toxic. We are creating a new class of therapies that can pinpoint solid tumors and metastases without harming surrounding tissue, enabling targeted treatment across a wide range of cancers.